Latest Commercialisation Strategy News

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.

Rhythm Biosciences has formalised a strategic co-marketing partnership with the Know Your Lemons Foundation to promote its geneType Breast Cancer Risk Assessment Test, expanding access to early detection tools for women in the US and Australia.

Impact Minerals’ 50%-owned Alluminous Pty Ltd advances its proprietary HiPurA® High Purity Alumina technology with new leadership and pilot plant commissioning, attracting strong customer interest.

AnteoTech has appointed Merrill Gray as its new Managing Director and CEO following a successful interim period, while issuing over 22 million shares to staff under its FY2025 incentive program.

AnteoTech has mutually terminated its A$1.4 million Queensland government grant to avoid costly co-investment, opting instead for cheaper third-party testing to advance its Ultranode™ battery technology.

Green360 Technologies has successfully raised A$4 million through a share placement to fund the commercialisation and scaling of its innovative low-carbon cement technology, supported by institutional investors and strengthened leadership.

EBR Systems has won final CMS approval for New Technology Add-On Payment reimbursement, paving the way for Medicare coverage of its innovative WiSE cardiac pacing system starting October 2025.

Nanollose Limited has completed a successful pilot manufacturing run blending its Nullarbor-20 fibre with wool, raised $1.05 million through an entitlement issue, and appointed Andrew Moullin as CEO to drive its commercialisation strategy.

Tryptamine Therapeutics has initiated the first-ever clinical trial using IV-infused psilocin to treat Binge Eating Disorder, with patient dosing set to begin shortly and results expected by year-end.

Terragen Holdings reports rapid customer growth for its new dry probiotics, secures a US patent, and posts promising crop trial results, signaling strong momentum in its agricultural biotech offerings.

Anatara Lifesciences reports Phase II GaRP-IBS trial results showing no safety concerns but missing the primary efficacy endpoint, while securing key patents and receiving a significant R&D tax refund.

ClearVue Technologies has appointed Douglas Hunt as its permanent Global CEO, unveiling a refreshed leadership team focused on scaling sales, manufacturing, and product innovation. The new executives have agreed to sub-market pay until the share price hits 35 cents, signaling strong alignment with shareholder interests.